Moderate riskFDA DrugClass II

Ascend metoprolol succinate ER tablets recalled for failed dissolution

Ascend Laboratories is recalling one lot of metoprolol succinate extended-release 25 mg tablets because they failed to meet dissolution specifications. This means the tablets may not break down and release the medication properly in the body. The affected lot was distributed nationwide.

From the FDA notice · Read the official notice ↗ · All Ascend Laboratories recalls

What to do

  1. Check if you take metoprolol succinate extended-release 25 mg from Ascend Laboratories (NDC 67877-590-01, lot #25140859, expiration Jan 2027).
  2. Contact your pharmacist or doctor if you have this medication.
  3. Do not stop taking your metoprolol without talking to your doctor first.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-590-01.
Sold in
Nationwide
Made for
Adults (0 months and older)

Details

Units affected
17,304 100-count bottles
Illnesses reported
None reported
Manufactured in
135 Us Highway 202 206 Ste 15, Bedminster, NJ, United States
Classification
Class II
Recall number
D-0547-2026

In the FDA's words

Description
Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-590-01. Failed Dissolution Specifications Lot # 25140859; Exp. Date: Jan 2027 Distribution: U.S. Nationwide Affected quantity: 17,304 100-count bottles
Hazard
Failed Dissolution Specifications

More from Ascend Laboratories

See all

Related topics

PotencyDrugsSold nationwideMore from FDA Drug